Table 1 Comparisons of baseline clinical parameters of the 116 HCC patients.

From: Human leukocyte antigen-G in hepatocellular carcinoma driven by chronic viral hepatitis or steatotic liver disease

Clinical and demographic parameters

Age at diagnosis (yrs): mean ± σ

65.21 ± 9.25

 

n

%

Male

97

83.62

Female

19

16.38

Etiology

Viral infections

95

81.91

HBV

32

27.59

HBV + HCV

8

6.90

HCV

55

47.41

SLD (ALD or MASLD/MASH)

21

18.10

Cirrhosis at diagnosis

109

93.97

Child–Pugh Score

A

97

83.62

B

15

12.93

C

4

3.45

BCLC staging system

0

15

12.93

A

68

58.62

B

26

22.41

C

4

3.45

D

3

2.59

Therapy

RFA

42

36.21

TACE

35

30.16

Surgical resection

13

11.21

Sorafenib

13

11.21

Other treatment

13

11.21

Radiological response to therapy at 1 year

CR

78

67.24

PR

7

6.03

PD

24

20.68

SD

7

6.03

Overall survival

1 year

93

80.17

3 years

54

46.55

5 years

30

25.86

  1. HBV: Hepatitis B virus, HBV + HDV: co-infection Hepatitis B virus-Hepatitis D virus, HCV: Hepatitis C virus, SLD :Steatotic liver disease, ALD: Alcoholic liver disease, MASLD:Metabolic dysfunction associated steatotic liver disease, MASH: Metabolic dysfunction associated steatohepatitis, BCLC Barcelona clinic liver cancer, RFA: Radiofrequency ablation, TACE: transarterial chemoembolization, CR: complete response, PR: partial response, PD: progression disease, SD: stable disease. P values were calculated for comparisons between HCC patients and healthy controls. Abbreviations: σ = standard deviation;.
Back to article page